TYRA BIOSCIENCES INC (TYRA)
Health Care · Precision Oncology / Targeted Cancer Therapeutics · NASDAQ
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly targeting FGFR-driven diseases.
What TYRA BIOSCIENCES INC does
Tyra Biosciences is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for cancers driven by specific genetic mutations. The company focuses on precision oncology programs designed to address unmet needs in patients with genetically-defined malignancies. Tyra leverages its research and development efforts to advance multiple product candidates through preclinical and clinical development stages.
Themes: precision oncology, targeted cancer therapies, kinase inhibitors, clinical-stage biotech
Fundamentals
- Price$26.05 as of 2026-08-21 close
- Market cap$1.6B as of 2026-08-21
- 1-year return+122.6% 2025-08-21 close $11.70 → 2026-08-21 close $26.05
- P/En/a earnings data not available
- ROE-46.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.72 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How TYRA compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How TYRA BIOSCIENCES INC looks technically
TYRA BIOSCIENCES INC (TYRA) is trading 12.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 7 trading days ago. It is 35.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 12.0% below its 200-day average, the long-term trend line — a long-term downtrend | -12.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $29.63 | $29.63 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.61 | $29.61 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 29.72. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal | 225 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control | 27.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($24.61 to $32.99) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 17.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $40.65 | $40.65 |
|---|---|---|
| From the 52-week high | it is 35.9% below its 52-week high (its highest price of the past year) | -35.9% |
| Above the 52-week low | it is 161.5% above its 52-week low (its lowest price of the past year) | +161.6% |
| Below the 52-week high | it is 35.9% below its highest point of the past year | 35.9% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $40.65 (set on 2026-04-01) | $40.65 |
| Given back of the 52-week move | over the past year its closes ranged ($10.20 to $39.61), and it has given back around half of its rise from last year’s low — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.49 to $21.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 46.1% |
| From the all-time high | it is 35.9% below its all-time high | -35.9% |
| Nearest price level | it is trading 5.1% above a support level at $24.72 — a price it turned at three times since 2026-02-12, most recently on 2026-08-14. Since 2024-08-21 it has 10 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.1% |
| All-time low | its lowest closing price on record is $5.02 (set on 2022-06-14) | $5.02 |
| Above the all-time low | it is 418.9% above its all-time low | +418.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 95% of the past ~6 months) | 95th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.58 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.58 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.23 and $33.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.23 – $27.98 – $33.73 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges below its 200-day average price (12.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.82× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.9% since the prior reading | -1.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.0% |
|---|---|---|
| Open gap | it gapped 10.2% below the previous close 12 sessions ago and has not traded back through the level it left behind at 32.53 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.2% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.5 percentage points (the stock lost 18.2% while the market gained 2.3%) | -20.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.2 percentage points (the stock lost 21.1% while the market gained 3.1%) | -24.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 28.6 percentage points (the stock lost 17.5% while the market gained 11.1%) | -28.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 102.2 percentage points (the stock gained 122.6% while the market gained 20.5%) | +102.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -14.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $32.54 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -19.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $26.17 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -0.5% |
Price levels it has turned at before
TYRA last closed at $26.05 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.72 | Support | 5.1% below the last close | turned there three times · 2026-02-12 to 2026-08-14 |
| $29.53 | Resistance | 13.4% above the last close | turned there three times · 2024-10-24 to 2026-07-23 |
| $20.19 | Support | 22.5% below the last close | turned there twice · 2024-10-10 to 2025-12-02 |
| $32.35 | Resistance | 24.2% above the last close | turned there twice · 2026-01-27 to 2026-05-07 |
| $33.70 | Resistance | 29.4% above the last close | turned there five times · 2026-02-12 to 2026-07-30 |
| $17.14 | Support | 34.2% below the last close | turned there twice · 2024-11-25 to 2025-01-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $29.72.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $26.65 and $28.93 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $24.61.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently CUT · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$50.82 range $39.00 – $59.00; median $53.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TYRA
- Consensus EPS estimate-$0.6836 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: the company must successfully advance its product candidates through preclinical studies and clinical trials, which are subject to inherent uncertainties in safety, efficacy, and regulatory approval outcomes","Regulatory and approval uncertainty: even if clinical trials are successful, the company faces risks in obtaining FDA approval and market authorization for its product candidates","Capital requirements and financing risk: as a clinical-stage biotech with significant R&D expenses, the company requires substantial capital to fund operations and may need to raise additional equity or debt, which could dilute existing shareholders or impose unfavorable terms"]
What changed in the latest 10-Q
AI-assisted comparison of TYRA's 10-Q filed 2026-05-13 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-13) references 'financial statements and notes thereto for the year ended December 31, 2025' and '2025 Annual Report' versus older filing's reference to December 31, 2024 and 2024 Annual Report
- Newer filing states SNÅP platform enables development of 'wholly-owned pipeline of oral small molecule product candidates'
- Newer filing specifies program indications as 'urothelial cancers and skeletal dysplasia conditions' with explicit mention that 'Alterations in the protein receptor FGFR3 are a validated driver in multiple indications'
- Newer filing states 'oral dabogratinib has been administered to over 100 participants across multiple clinical studies'
- Newer filing describes 'dabogratinib 3x3' strategy explicitly naming the approach
- Newer filing specifies SURF303 doses as '60 mg and 80 mg once daily'
- Newer filing states SURF302 has 'more than 20 patients enrolled at US and international trial sites'
- Newer filing states expectation to report 'initial three-month complete response data from both dose cohorts in August 2026' for SURF302
- Newer filing specifies BEACH301 enrollment as starting with 'sa' (text appears truncated)
- Removed:
- Older filing (2025-11-05) referenced pipeline products 'TYRA-430 and TYRA-200: three clinical-stage, novel small molecules' which are not mentioned in newer filing
- Older filing stated dabogratinib was 'formerly TYRA-300' nomenclature not included in newer filing
- Older filing described 'initial focus on Fibroblast Growth Factor Receptor (FGFR) biology' versus newer filing's 'harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology'
- Older filing described BEACH301 as having 'commenced enrolling a safety sentinel cohort planned for at least 3 participants per dose level' with 'dosed the first child in this study in August 2025' and interim results expected 'in the second half of 2026'
- Older filing stated SURF302 'will enroll up to 90 participants' and 'Following a review of efficacy and safety, an additional dosing cohort may be evaluated'
- Older filing stated SURF302 'dosed the first patient in this study in June 2025' and expected 'initial three-month CR data in the first half of 2026'
- Older filing stated SURF303 was 'recently expanded' and 'An investigational new drug application was cleared by the U.S. Food and Drug Administration in October 2025' with expectation to 'initiate this study in 2026'
- Older filing referenced ongoing SURF301 Phase 1/2 trial structure and design narrative
- Reworded:
- Older filing stated 'Mutations in the protein receptor FGFR3 are a key driver' changed to newer filing's 'Alterations in the protein receptor FGFR3 are a validated driver'
- Older filing used 'skeletal conditions and bladder cancer' language changed to newer filing's 'urothelial cancers and skeletal dysplasia conditions'
- Older filing described indications as 'pediatric achondroplasia (BEACH301), treatment of low-grade intermediate risk non-muscle invasive bladder cancer (SURF302), our recent expansion into the treatment of low-grade upper tract urothelial carcinoma (SURF303), and potentially for the treatment of metastatic urothelial carcinoma (SURF301)' versus newer filing's narrative describing SURF301 as already demonstrating 'initial clinical proof-of-concept results' with Phase 2 trials as current advancement
- Newer filing describes SURF303 as 'designed as a potential registrational trial' versus older filing stating it was 'recently expanded' with FDA clearance in October 2025
- Notes:
- Both filings appear truncated at the end of the BEACH301 and SURF301 sections, limiting complete comparison of those program descriptions
- The newer filing's text cuts off mid-sentence ('The study has enrolled the sa'), preventing full assessment of BEACH301 enrollment details
- Older filing's SURF301 description also cuts off mid-sentence ('was designed to determine the optimal an')
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for TYRA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding TYRA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,229,451
- Reported value $430,087,962
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TYRA had 9,246,935 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TYRA had 15.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.83 days to cover at the same settlement.
- Reported short interest (shares) 9,246,935
- Short interest (% of shares outstanding) 15.5%
- Prior settlement (shares) 9,930,770
- Reported change -6.89%
- Days to cover (reported) 17.83
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Blueprint Medicines (BPMC)
- BridgeBio Pharma (BBIO)
- Relay Therapeutics (RLAY)
- Revolution Medicines (RVMD)
- Mirati Therapeutics (MRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TYRA vs…
TYRA BIOSCIENCES INC is found in…
Frequently asked questions
What does TYRA BIOSCIENCES INC (TYRA) do?
Tyra Biosciences is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for cancers driven by specific genetic mutations. The company focuses on precision oncology programs designed to address unmet needs in patients with genetically-defined malignancies. Tyra leverages its research and development efforts to advance multiple product candidates through preclinical and clinical development stages.
What sector is TYRA BIOSCIENCES INC (TYRA) in?
TYRA BIOSCIENCES INC (TYRA) is classified in the Health Care sector. Its industry is Precision Oncology / Targeted Cancer Therapeutics. It trades on NASDAQ.
Who are TYRA BIOSCIENCES INC's (TYRA) competitors?
Notable peers of TYRA BIOSCIENCES INC (TYRA) include Blueprint Medicines, BridgeBio Pharma, Relay Therapeutics, Revolution Medicines and Mirati Therapeutics. This peer set is informational only — not financial advice.
Is TYRA BIOSCIENCES INC (TYRA) overbought or oversold right now?
TYRA BIOSCIENCES INC (TYRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TYRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.